Skip to Content

Wendy A. Woodward, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Service Chief, Breast Cancer Radiation Oncology Program, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Woodward is an Associate Professor and the Section Chief of Clinical Breast Radiation in Department of Radiation Oncology at The University of Texas M. D. Anderson Cancer Center (MDACC). She is a physician-scientist specializing in clinical breast radiation oncology with a lab focused on breast cancer stem cell biology and radiobiology.  She is deputy director of the MDACC Inflammatory Breast Cancer clinic and Research Program and is dedicated to advancing the radiation treatment and biologic understanding of inflammatory breast cancer through laboratory, translational, and clinical research.  Nationally, she serves as the liaison between the breast working group and the translational research program in the Radiation Therapy Oncology Group devoted to designing translational endpoints for multi-institutional trials in breast radiation therapy. Specific interests include studying molecular determinants of treatment resistance in breast cancer stem cells and novel treatment of inflammatory breast cancer. Finally, Dr. Woodward has a strong interest in education and mentoring trainees in both clinical and translational breast cancer research and received the Chamberlain Outstanding Mentorship Award at MDACC in 2014.

Education & Training

Degree-Granting Education

2000 Jefferson Medical College, Philadelphia, PA, MD, Medicine
2000 Thomas Jefferson University, Philadelphia, PA, PHD, Biochemistry and Molecular Biology
1993 Mount Holyoke College, S. Hadley, MA, BA, Cum Laude, High Honors, Chemistry

Postgraduate Training

9/2003-9/2004 Research Fellowship, Mammary Gland Biology, Baylor College of Medicine, Houston, TX, Jeff M. Rosen, Ph.D.
7/2001-6/2005 Clinical Residency, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Thomas A. Buchholz, M.D
7/2001-8/2000 Internal Medicine, Albert Einstein Medical Center, Philadelphia, PA, Glenn Eiger, M.D.

Board Certifications

6/2006 American Board of Radiology (Radiation Oncology)


Academic Appointments

Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2005-8/2011

Honors and Awards

2014 Robert M. Chamberlain Distinguished Mentor Award, The University of Texas MD Anderson Cancer Center
2011 Finalist, 2011 Robert M. Chamberlain Distinguished Mentor Award, MD Anderson Postdoctoral Association
2008 RTOG Next Generation Investigator Award, Radiation Therapy Oncology Group
2006 Travel Grant to the Translational Research Symposium, ASTRO
2005 Gilbert H. Fletcher Award, The University of Texas M. D. Anderson Cancer Center, Residency Research Award
2005 Travel Grant to the Gordon Research Conference, ASTRO
2004 Roentgen Research Award, Radiological Society of North America
2003 Merit Award, American Society of Clinical Oncology
2003 Young Oncologist Essay Award, American Radium Society

Selected Publications

Peer-Reviewed Original Research Articles

1. Wolfe AR, Atkinson RL, Reddy JP, Debeb BG, Larson R, Li L, Masuda H, Brewer T, Atkinson BJ, Brewster A, Ueno NT, Woodward, WA. High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. Int J Radiat Oncol Biol Phys 91(5):1072-1080, 4/2015. PMID: 25832697.
2. Debeb BG, Smith DL, Li L, Larson R, Xu W, Woodward WA. Differential effect of phosphorylation-defective survivin on radiation response in estrogen receptor-positive and -negative breast cancer. PLoS One 10(3):e0120719, 3/2015. PMID: 25763854.
3. Caceres S, Pena L, de Andres PJ, Illera MJ, Lopez MS, Woodward WA, Reuben JM, Illera JC. Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366. PLoS One. e-Pub 3/2015. PMID: 25807360.
4. Strom EA, Amos RA, Shaitelman SF, Kerr MD, Hoffman KE, Smith BD, Tereffe W, Stauder MD, Perkins GH, Amin MD, Wang X, Poenisch F, Ovalle V, Buchholz TA, Babiera G, Woodward WA. Proton partial breast irradiation in the supine position: Treatment description and reproducibility of a multibeam technique. Practical Radiation Oncology. e-Pub 3/2015. PMID: 25804105.
5. Woodward, WA. Should surgery referral be standard practice in metastatic inflammatory breast cancer? Ann Surg Oncol. e-Pub 3/2015. PMID: 25794829.
6. Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res 17(1). e-Pub 1/2015. PMID: 25572591.
7. Thaker NG, Hoffman KE, Stauder MC, Shaitelman SF, Strom EA, Tereffe W, Smith BD, Perkins GH, Huo L, Munsell MF, Pusztai L, Buchholz Ta, Woodward WA. The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. Springerplus. e-Pub 1/2015. PMID: 25674496.
8. Shaitelman SF, Buchholz TA, Hunt KK, Hortobagyi GN, Schlembach P, Arzu I, Bloom E, Chronowski G, Dvorak T, Grade E, Hoffman KE, Perkins GH, Reed V, Shah S, Stauder MC, Strom EA, Tereffe W, Woodward WA, Ensor J, Smith BD. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at six months compated to conventionally fractionated whole breast irradiation: results of a randomized Trial. Int J Radiat Oncol Biol Phys 90(5):1264, 12/2014. PMID: 25539386.
9. Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, Anfossi S, Jackson S, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Khoury JD, Cristofanilli M, Reuben JM. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost 113(2). e-Pub 11/2014. PMID: 25373787.
10. Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y, Zhang J, Yuan J, Wang M, Chen D, Sun Y, Woodward WA, Liu Y, Dean DC, Liang H, Hu Y, Ang KK, Hung MC, Chen J, Ma L. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol 16(9):864-75, 9/2014. e-Pub 8/2014. PMCID: PMC4150825.
11. Woodward WA, Sneige N, Winter K, Kuerer HM, Hudis C, Rakovitch E, Smith BL, Pierce LJ, Germano I, Pu AT, Walker EM, Grisell DL, White JR, McCormick B, for the Radiation Therapy Oncology Group (RTOG). Web based pathology assessment in RTOG 98-04. J Clin Pathol 67(9):777-780, 9/2014. PMCID: PMC4145412.
12. Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the American College of Surgeons Oncology Group Z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neodajuvant chemotherapy? Ann Surg Oncol 21(8):2468-73, 8/2014. e-Pub 5/2014. PMID: 24841348.
13. Woodward WA. Postmastectomy radiation therapy for inflammatory breast cancer: is more better? Int J Radiat Oncol Biol Phys 89(5):1004-1005, 8/2014. e-Pub 7/2014. PMID: 25035202.
14. Debeb BG, Gong Y, Atkinson RL, Sneige N, Huo L, Gonzalez-Angulo A, Hung MC, Valero V, Ueno NT, Woodward WA. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. J Exp Clin Cancer Res 33(1). e-Pub 7/2014. PMID: 25051981.
15. Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Hortobágyi GN, Buchholz TA, Ueno NT, Woodward WA. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med 3(7):849-56, 7/2014. e-Pub 5/2014. PMCID: PMC4073823.
16. Gong Y, Wang J, Huo L, Wei W, Ueno NT, Woodward WA. Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining. Clin Breast Cancer 14(3):e81-8, 6/2014. e-Pub 12/2013. PMID: 24461456.
17. McBride A, Allen P, Woodward WA, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz TA. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys 89(2):392-398, 6/2014. e-Pub 4/2014. PMID: 24721590.
18. Akay CL, Ueno NT, Chisholm GB, Hortobagyi GN, Woodward WA, Alvarez RH, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera GV. Primary tumor resection as a component of multimodality treatment may improve local control and survival in stage IV inflammatory breast cancer. Cancer 120(9):1319-28, 5/2014. e-Pub 2/2014. PMID: 24510381.
19. Yang J, Woodward WA, Reed VK, Strom EA, Perkins GH, Tereffe W, Buchholz TA, Zhang L, Balter P, Court LE, Li XA, Dong L. Statistical modeling approach to quantitative analysis on inter-observer variability in breast contouring. Int J Radiat Oncol Biol Phys 89(1):214-221, 5/2014. e-Pub 3/2014. PMCID: PMC3997068.
20. Shaitelman SF, Khan AJ, Woodward WA, Arthur DW, Cuttino LW, Bloom ES, Shah C, Freedman GM, Wilkinson JB, Babiera GV, Julian TB, Vicini FA. Shortened radiation therapy schedules for early-stage breast cancer: A review of hypofractionated whole-breast irradiation and accelerated partial breast irradiation. Breast J 20(2):131-46, Mar-Apr, 3/2014. e-Pub 1/2014. PMID: 24479632.
21. MacDermed DM, Houtman KM, Thang SH, Allen PK, Caudle AS, Gainer SM, Hunt KK, Perkins GH, Shaitelman SF, Smith BD, Strom EA, Tereffe W, Woodward WA, Buchholz TA, Hoffman KE. Therapeutic radiation dose delivered to the low axilla during whole breast radiotherapy in the prone posistion: implications for targeting the undissected axilla. Pract Radiat Oncol 4(2):116-122, Mar-Apr, 3/2014. e-Pub 7/2013. PMID: 24890352.
22. Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, Viens P, Symmans WF, Birnbaum D, Van Laere SJ. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol 25(2):358-65, 2/2014. e-Pub 12/2013. PMCID: PMC3905779.
23. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 25(2):384-91, 2/2014. e-Pub 12/2013. PMCID: PMC3905780.
24. Woodward WA, Koay E, Takiar V. Radiation therapy for inflammatory breast cancer: technical considerations and diverse clinical scenarios. Breast Cancer Manage 3(1):43-52, 1/2014.
25. Woodward WA, Krishnamurthy S, Lodhi A, Xiao L, Gong Y, Cristofanilli M, Buchholz TA, Lucci A. Aldehyde dehydrogenase1 immunohistochemical staining in primary breast cancer cells independently predicted overall survival but did not correlate with the presence of circulating or disseminated tumors cells. J Cancer 5(5):360-367, 2014. e-Pub 4/2014. PMCID: PMC4007524.
26. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG, Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA, Reuben JM. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of facorable clinical outcome in patients with metastatic HER2(+) inflammatory breast cancer. PLoS One 9(1):e83113, 2014. e-Pub 1/2014. PMCID: PMC3885405.
27. Zhang P, Wang L, Rodriguez-Aguayo C, Yuan Y, Debeb BG, Chen D, Sun Y, You MJ, Liu Y, Dean DC, Woodward WA, Liang H, Yang X, Lopez-Berestein G, Sood AK, Hu Y, Ang KK, Chen J, Ma L. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun 5:5671, 2014. e-Pub 12/2014. PMID: 25476932.
28. Smith D, Kong F, Yang D, Larson R, Sims-Mourtada J, Woodward WA. Patched targeted peptides for imaging and treatment of hedgehog positive breast tumors. Biomed Res Int 2014:525680, 2014. e-Pub 9/2014. PMCID: PMC4172929.
29. Takiar V, Akay CL, Stauder MC, Tereffe W, Alvarez RH, Hoffman KE, Perkins GH, Strom EA, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Springerplus 3:166, 2014. e-Pub 3/2014. PMCID: PMC3977020.
30. Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans WF, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res 15(6). e-Pub 11/2013. PMID: 24274653.
31. Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 promotes the develpment and progression of inflammatory breast cancer through activation of Ax1 Kinase. Cancer Res 73(21):6516-25, 11/2013. e-Pub 9/2013. PMID: 24014597.
32. Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K, Krishnamurthy S, Tin S, Cristofanilli M, Hortobagyi GN, Woodward WA, Lucci A, Reuben JM. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Ann Oncol 24(10):2515-21, 10/2013. e-Pub 6/2013. PMCID: PMC3784333.
33. Wang X, Zhang X, Li X, Amos RA, Shaitelman SF, Hoffman K, Howell R, Salehpour M, Zhang SX, Sun TL, Smith B, Tereffe W, Perkins GH, Buchholz TA, Strom EA, Woodward WA. Accelerated partial-breast irradiation using intensity-modulated proton radiotherapy: do uncertainties outweigh potential benefits? Br J Radiol 86(1029):20130176, 9/2013. e-Pub 5/2013. PMCID: PMC3755395.
34. Atkinson RL, Yang WT, Rosen DG, Landis MD, Wong H, Lewis MT, Creighton CJ, Sexton KR, Hilsenbeck SG, Sahin AA, Brewster AM, Woodward WA, Chang JC. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Res 15(5). e-Pub 9/2013. PMID: 24008095.
35. Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix L, Reuben JM, Bertucci F. Uncovering the molecular secrets of inflammatory breast cancer biology: An integrated analysis of three distinct affymetrix gene expression data sets. Clin Cancer Res 19(17):4685-4696, 9/2013. e-Pub 2/2013. PMID: 23396049.
36. Kim MM, Allen P, Gonzalez-Angulo AM, Woodward WA, Meric-Bernstam F, Buzdar AU, Hunt KK, Kuerer HM, Litton JK, Hortobagyi GN, Buchholz TA, Mittendorf EA. Pathologic complete response to neoadjuvant chemotherapy with Trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol 24(8):1999-2004, 8/2013. e-Pub 4/2013. PMCID: PMC3718505.
37. Xu W, Lacerda L, Debeb BG, Atkinson RL, Solley T, Li L, Orton D, McMurray JS, Hang BI, Lee E, Klopp A, Ueno NT, Reuben JM, Krishnamurthy S, Woodward WA. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One 8(e71508), 8, 8/2013. PMID: 24013655.
38. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer. e-Pub 7/2013. PMID: 23820253.
39. Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy. Am J Clin Oncol. e-Pub 5/2013. PMID: 23648437.
40. Skinner HD, Strom EA, Motwani SB, Woodward WA, Green MC, Babiera G, Booser DJ, Meric-Bernstam F, Buchholz TA. Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiat Oncol 8(1):13, 1/2013. PMID: 23311297.
41. Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS, Woodward WA, Lu K, Salimian B, Nagrath D, Klopp AH. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS One 8(12):e81859, 2013. e-Pub 12/2013. PMCID: PMC3847080.
42. Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA, Woodward WA. Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/B-catenin signaling. Stem Cells 30(11):2366-2377, 11/2012. PMID: 22961641.
43. Kim MM, Dawood S, Allen P, Sahin AA, Woodward WA, Smith BD, Strom EA, Hunt KK, Meric-Bernstam F, Gonzalez-Angulo AM, Buchholz TA. Hormone receptor status influences the locoregional benefit of Trastuzumab in patients with non-metastatic breast cancer. Cancer 118(20):4936-43, 10/2012. e-Pub 4/2012. PMID: 22511276.
44. Iyengar P, Strom EA, Zhang YJ, Whitman GJ, Smith BD, Woodward WA, Yu TK, Buchholz TA. The value of ultrasound in detecting extra-axillary regional node involvement in patients with advanced breast cancer. Oncologist 17(11):1402-1408, 9/2012. PMID: 22982581.
45. Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A, Ueno NT, Buchholz TA. Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. Int J Radiat Oncol Biol Phys 83(5):1381-6, 8/2012. e-Pub 1/2012. PMID: 22284689.
46. Debeb BG*, Cohen EN*, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA, Woodward WA (*co-first authors). Pre-clinical studies of notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat 134(2):495-510, 7/2012. e-Pub 5/2012. PMID: 22547109.
47. Pinnix C, Perkins GH, Strom EA, Tereffe W, Woodward W, Oh JL, Arriaga L, Munsell MF, Kelly P, Hoffman KE, Smith BD, Buchholz TA, Yu TK. Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial. Int J Radiat Oncol Biol Phys 83(4):1089-94, 7/2012. e-Pub 12/2011. PMID: 22172912.
48. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol 23(4):870-5, 4/2012. e-Pub 7/2011. PMID: 21765048.
49. Klopp AH, Zhang Y, Solley T, Amaya-Manzanares F, Marini F, Andreeff M, Debeb B, Woodward WA, Schmandt R, Broaddus R, Lu K, Kolonin MG. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res 18(3):771-82, 2/2012. e-Pub 12/2011. PMCID: PMC3481843.
50. Sims-Mourtada J, Yang D, Tworowska I, Larson R, Smith D, Tsao N, Opdenaker L, Mourtada F, Woodward WA. Detection of Canonical Hedgehog Signaling in Breast Cancer by 131 iodine labeled derivatives of the Sonic Hedgehog protein. J Biomed Biotechnol 2012:639562, 2012. e-Pub 6/2012. PMCID: PMC3395403.
51. Amos RA, Woodward WA. Field match verification during combination proton, photon and electron therapy for oligometastatic inflammatory breast cancer. Med Dosim 37(4):442-4, 2012. e-Pub 5/2012. PMID: 22609618.
52. Nagar H, Mittendorf EA, Strom EA, Perkins GH, Oh JL, Tereffe W, Woodward WA, Gonzalez-Angulo AM, Hunt KK, Buchholz TA, Yu TK. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically-staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys 81(3):782-7, 11/2011. e-Pub 8/2011. PMID: 21885207.
53. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 11(5):325-331, 10/2011. e-Pub 7/2011. PMID: 21764391.
54. Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam F. Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol 18(11):1364-1373, 10/2011. e-Pub 9/2011. PMID: 21947595.
55. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 20(3):341-356, 9/2011. PMCID: PMC3172580.
56. Wang X, Amos RA, Zhang X, Taddei PJ, Woodward WA*, Hoffman KE, Yu TK, Tereffe W, Oh J, Perkins GH, Salehpour M, Zhang SX, Sun TL, Gillin M, Buchholz TA, Strom EA (*corresponding author). External-Beam Accelerated Partial Breast Irradiation Using Multiple Proton Beam Configurations. Int J Radiat Oncol Biol Phys 80(5):1464-72, 8/2011. e-Pub 8/2010. PMCID: PMC3249354.
57. Reddy JP, Levy L, Oh JL, Strom EA, Perkins GH, Buchholz TA, Woodward WA. Long-Term Outcomes in Patients with Isolated Supraclavicular Nodal Recurrence After Mastectomy and Doxorubicin-Based Chemotherapy for Breast Cancer. Int J Radiat Oncol Biol Phys 80(5):1453-7, 8/2011. e-Pub 12/2010. PMID: 21168284.
58. Woodward WA, Gao H*, Cohen E*, Li L, Xu W, Debeb BG, Jimenez CA, Krishnamurthy S, Tucker SL, Hortobagyi GN, Cristofanilli M, Buchholz TA, Reuben JM (*co-second authors). Percentage of CD45-CD326+ CD44+CD24-/lo cells in pleural effusion fluid of patients with metastatic breast cancer predicts for overall survival. Interventional Oncology 1(1):4-10, 8/2011.
59. Albert JM, Buzdar AU, Guzman R, Allen PK, Strom EA, Perkins GH, Woodward WA, Hoffman KE, Tereffe W, Hunt KK, Buchholz TA, Oh JL. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat 128(2):421-7, 7/2011. e-Pub 5/2011. PMID: 21553292.
60. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9):1819-26, 5/2011. e-Pub 11/2010. PMID: 21509759.
61. Xu W, Debeb BG, Lacerda L, Li J, Woodward WA. Tetrandrine, a compound common in Chinese traditional medicine, preferentially kills breast cancer tumor initiating cells (TICs) in vitro. Cancers 3(2):2274-2285, 5/2011. PMID: 24212809.
62. Fontanilla HP, Woodward WA, Lindberg ME, Zhang L, Sharp HJ, Strom EA, Salehpour M, Buchholz TA, Dong L. Automating RTOG-defined target columes for postmastectomy radiation. Practical Radiation Oncology 1(2). e-Pub 4/2011. PMID: 24673923.
63. Dawood S, Merajver SD, Vients P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22(3):515-523, 3/2011. PMID: 20603440.
64. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN, Hung MC. EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-ß-Catenin Signaling. Cancer Cell 19(1):86-100, 1/2011. e-Pub 1/2011. PMCID: PMC3041516.
65. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist 16(12):1675-83, 2011. e-Pub 12/2011. PMCID: PMC3248766.

Last updated: 3/30/2015